• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Longboard Pharmaceuticals Inc. (Amendment)

    2/13/24 4:07:37 PM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LBPH alert in real time by email
    SC 13G/A 1 tm245871d3_sc13ga.htm SC 13G/A

     

     

         
      UNITED STATES  
      SECURITIES AND EXCHANGE COMMISSION  
      Washington, D.C. 20549  
         

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*

     

    Longboard Pharmaceuticals, Inc.

    (Name of Issuer)

     

    Voting Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    54300N103

    (CUSIP Number)

     

    February 6, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    o Rule 13d-1(b)
    x Rule 13d-1(c)
    o Rule 13d-1(d)

     

    *       The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

      1. Name of Reporting Persons:
    HBM Healthcare Investments (Cayman) Ltd.
      2. Check the Appropriate Box if a Member of a Group
        (a) o
        (b) o
      3. SEC Use Only
      4. Citizenship or Place of Organization:
    Cayman Islands, British West Indies
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power:
    0
    6. Shared Voting Power:
    0
    7. Sole Dispositive Power:
    0
    8. Shared Dispositive Power:
    0
      9. Aggregate Amount Beneficially Owned by Each Reporting Person:
    0
      10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
         
      11. Percent of Class Represented by Amount in Row (9):
    0%
      12. Type of Reporting Person (See Instructions):
    CO
             

     

     

     

     

     

    Item 1. (a). Name of Issuer:
    Longboard Pharmaceuticals, Inc.
      (b).

    Address of Issuer’s Principal Executive Offices:
    4275 Executive Square, Suite 950

    La Jolla, California 92037

    Item 2(a).  

    Name of Person Filing:

    HBM Healthcare Investments (Cayman) Ltd.

    Item 2(b).  

    Address of Principal Business Office:

    Governors Square

    23 Lime Tree Bay Avenue

    PO Box 30852

    Grand Cayman, Cayman Islands

    Item 2(c).  

    Citizenship:

     

    Cayman Islands, British West Indies

    Item 2(d).   Title of Class of Securities:
    Voting Common Stock, par value $0.0001
    Item 2(e).   CUSIP Number:
    54300N103

    Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
      Not Applicable.
    Item 4. Ownership.
      (a)

    Amount beneficially owned:

     

    0 

      (b)

    Percent of class:

     

    0% 

      (c) Number of shares as to which the Reporting Person has:
        (i)

    Sole power to vote or to direct the vote:

     

    0 

        (ii)

    Shared power to vote or to direct the vote:

     

    0 

        (iii)

    Sole power to dispose or to direct the disposition of:

     

    0 

        (iv)

    Shared power to dispose or to direct the disposition of:

     

    0 

           

     

     

     

     

    Item 5. Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x 
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
      Not Applicable.
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
      Not Applicable.
    Item 8. Identification and Classification of Members of the Group.
      Not Applicable.
    Item 9. Notice of Dissolution of Group.
      Not Applicable.

    Item 10.
    Certification.
              By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
       

     

     

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 13, 2024

     

     

    HBM HEALTHCARE INVESTMENTS (CAYMAN) LTD. 

         
      By: /s/ Jean-Marc LeSieur
      Name: Jean-Marc LeSieur
      Title: Managing Director

     

    SIGNATURE PAGE TO SCHEDULE 13G AMENDMENT NO. 2 (LONGBOARD PHARMACEUTICALS, INC.)

     

     

     

    Get the next $LBPH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LBPH

    DatePrice TargetRatingAnalyst
    9/10/2024$60.00Buy
    Truist
    7/1/2024$60.00 → $90.00Overweight
    Cantor Fitzgerald
    5/1/2024$36.00Outperform
    Robert W. Baird
    2/16/2024$40.00Buy
    Citigroup
    10/24/2023$16.00 → $35.00Overweight
    Cantor Fitzgerald
    4/27/2023$13.00Buy
    B. Riley Securities
    2/14/2022$14.00Outperform
    Wedbush
    More analyst ratings

    $LBPH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent Director

    Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the appointment of Amit Munshi, as Sensorion's independent director and Chairman of the Board, effective April 1, 2025. Mr. Munshi succeeds Mr. John Furey who stepped down as an Independent Board Member. Mr. Munshi is then appointed Chairman of the Board, replacing Khalil Barrage who served as the Company's interim Chairman since March 31, 2023. Mr. Barrage will continue to serve as a director on Sensorion's Board. This appointment by the Board of directors is performed b

    4/2/25 1:30:00 AM ET
    $LBPH
    $ARNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)

    DEEp OCEAN is the first pivotal clinical trial designed to study DEEs broadly Initial sites activated with additional sites expected to be activated in the coming weeks Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has initiated its global Phase 3 DEEp OCEAN Study evaluating its investigational drug bexicaserin for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) in participants two years of age and older. "The initiation of our second global Phase 3 clinical trial, DEEp OCEAN in DEEs, is a

    11/12/24 8:30:00 AM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

    Positive opinion of Paediatric Investigation Plan for bexicaserin issued by European Medicines Agency (EMA) Paediatric Committee (PDCO) for children down to the age of 2 years Recently initiated Phase 3 global clinical trial (the DEEp SEA Study) to evaluate bexicaserin in Dravet syndrome for participants ages 2-65 years Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported third quarter 2024 financial results. RECENT UPDATES: In October, announced an agreement for H. Lundbeck A/S (Lundbeck) to acquire Longboard in a stra

    11/7/24 4:01:00 PM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LBPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Lynch Casey

    4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)

    12/2/24 7:29:28 PM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Le Goff Corinne

    4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)

    12/2/24 7:27:57 PM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Sekhri Paul J

    4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)

    12/2/24 7:26:22 PM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LBPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CMO Kaye Randall bought $2,482 worth of shares (100 units at $24.82), sold $580,891 worth of shares (16,767 units at $34.64) and exercised 16,667 shares at a strike of $4.35 (SEC Form 4)

    4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)

    8/13/24 6:01:53 PM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LBPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on Longboard Pharmaceuticals with a new price target

    Truist initiated coverage of Longboard Pharmaceuticals with a rating of Buy and set a new price target of $60.00

    9/10/24 7:53:02 AM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald reiterated coverage on Longboard Pharmaceuticals with a new price target

    Cantor Fitzgerald reiterated coverage of Longboard Pharmaceuticals with a rating of Overweight and set a new price target of $90.00 from $60.00 previously

    7/1/24 12:54:07 PM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Robert W. Baird initiated coverage on Longboard Pharmaceuticals with a new price target

    Robert W. Baird initiated coverage of Longboard Pharmaceuticals with a rating of Outperform and set a new price target of $36.00

    5/1/24 6:27:25 AM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LBPH
    SEC Filings

    View All

    SEC Form 15-12G filed by Longboard Pharmaceuticals Inc.

    15-12G - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)

    12/12/24 8:10:02 AM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form POSASR filed by Longboard Pharmaceuticals Inc.

    POSASR - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)

    12/10/24 3:53:35 PM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form RW WD filed by Longboard Pharmaceuticals Inc.

    RW WD - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)

    12/10/24 3:40:14 PM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LBPH
    Leadership Updates

    Live Leadership Updates

    View All

    Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent Director

    Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the appointment of Amit Munshi, as Sensorion's independent director and Chairman of the Board, effective April 1, 2025. Mr. Munshi succeeds Mr. John Furey who stepped down as an Independent Board Member. Mr. Munshi is then appointed Chairman of the Board, replacing Khalil Barrage who served as the Company's interim Chairman since March 31, 2023. Mr. Barrage will continue to serve as a director on Sensorion's Board. This appointment by the Board of directors is performed b

    4/2/25 1:30:00 AM ET
    $LBPH
    $ARNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longboard Pharmaceuticals Announces the Appointment of Highly Accomplished Healthcare Executive Randall Kaye, M.D., as Chief Medical Officer

    SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the appointment of Dr. Randall Kaye as Chief Medical Officer (CMO). Dr. Philip Perera, who has led the clinical development and medical affairs activities since the launch of Longboard, has retired as CMO while remaining with Longboard in an advisory role. "On behalf of the board, shareholders, and our employees, I want to thank Phil for his tremendous contributions," said Kevin R. Lind, Longboard's President and Chief Executive Officer. "His outstanding leade

    3/21/22 4:01:00 PM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longboard Pharmaceuticals Provides Corporate Update and Reports Full Year 2021 Financial Results

    Initiated the Phase 1b/2a PACIFIC Study, evaluating LP352 in participants with developmental and epileptic encephalopathies (DEEs)LP352 demonstrated statistically significant reduction of epileptiform event frequency and duration in the scn1lab zebrafish model of Dravet syndromeLP659 IND submission remains on track for second half of 2022Cash position expected to support operations into 2024 based on current business plan SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) --  Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financ

    3/3/22 4:05:00 PM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LBPH
    Financials

    Live finance-specific insights

    View All

    Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline

    The proposed acquisition represents a significant step forward in Lundbeck's Focused Innovator strategy, adding a highly innovative and complementary product in late-stage development for Developmental and Epileptic Encephalopathies (DEEs) - an area of high unmet medical need The acquisition will enhance and complement Lundbeck's capabilities and presence within neuro-rare conditions The lead asset, bexicaserin, holds blockbuster potential and is in development for the treatment of DEEs in a program enrolling patients diagnosed with Dravet syndrome, Lennox-Gastaut syndrome, and other DEE syndromes Bexicaserin has shown encouraging anti-seizure effects to date in preclinical and clini

    10/14/24 6:30:00 AM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longboard Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

    Bexicaserin (LP352) received Breakthrough Therapy designation (BTD) for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) for patients two years of age or older Bexicaserin demonstrated a sustained, durable response in seizure reduction and a favorable safety and tolerability profile across a broad range of DEEs in an interim analysis of the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Completed End of Phase 2 Meeting to discuss Longboard's global Phase 3 program for bexicaserin, which is on track to initiate in H2 2024 Longboard plans to host an Investor & Analyst Event on September 16 to highlight details of the global P

    8/1/24 4:01:00 PM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longboard Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host Corporate Update Call on August 1

    Conference call to discuss corporate updates, including Phase 1 single ascending dose (SAD) topline data for LP659 in healthy volunteers Conference call and webcast to be held August 1 at 4:30pm ET (1:30pm PT) Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it plans to release second quarter 2024 financial results and provide a corporate update, including topline Phase 1 SAD data for LP659, its centrally acting, highly selective sphingosine-1-phosphate (S1P) receptor modulator, on August 1, 2024. The Company will host a conference call and we

    7/29/24 9:15:00 AM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LBPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Longboard Pharmaceuticals Inc.

    SC 13G/A - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)

    11/14/24 3:10:34 PM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Longboard Pharmaceuticals Inc.

    SC 13G/A - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)

    11/14/24 1:22:40 PM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Longboard Pharmaceuticals Inc.

    SC 13G/A - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)

    11/12/24 3:59:14 PM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care